A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (NCT06792695)

🧪 Interventions in This Study

• Volrustomig (DRUG)
• FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan) (DRUG)
• Bevacizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (76 Sites)

Showing the first 25 of 76 sites.

• Research Site — Scottsdale, Arizona
• Research Site — Los Angeles, California
• Research Site — Washington D.C., District of Columbia
• Research Site — Chicago, Illinois
• Research Site — Baltimore, Maryland
• Research Site — Boston, Massachusetts
• Research Site — Rochester, Minnesota
• Research Site — Trenton, New Jersey
• Research Site — Rochester, New York
• Research Site — Cleveland, Ohio
• Research Site — Portland, Oregon
• Research Site — Philadelphia, Pennsylvania
• Research Site — Nashville, Tennessee
• Research Site — Houston, Texas
• Research Site — East Melbourne,
• Research Site — Wollongong,
• Research Site — Woodville South,
• Research Site — Victoria, British Columbia
• Research Site — Barrie, Ontario
• Research Site — Toronto, Ontario
• Research Site — Montreal, Quebec
• Research Site — Beijing,
• Research Site — Chengdu,
• Research Site — Harbin,
• Research Site — Shanghai,

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Colorectal Cancer

• A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer — Phoenix, Arizona
• Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer — Toronto, Ontario
• A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) — Los Angeles, California
• A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer — Duarte, California
• A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer — Los Angeles, California
• Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation — Phoenix, Arizona

Explore by condition: All Metastatic Colorectal Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.